Abstract: The solar array (SA) serves as the sole energy source for satellites, continuously converting sunlight into electricity to power satellite operations. Sensors placed at key locations on the ...
The Milwaukee Journal Sentinel wants to know how the price of groceries is affecting your household. As the holiday shopping season gets into full swing, many shoppers are coping with buying gifts on ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Journal Sentinel preps reporter Zac Bellman previews the matchups of seven area football teams still alive in the WIAA playoffs entering Nov. 14. 2025 Fantasy Football Rankings: Justin Boone's top ...
Christmas and cookies go together like Thanksgiving and turkey, and the Journal Sentinel wants to help spread the festive cheer. We're running a list of area cookie sales in our Food section on Dec. 3 ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
Who was the Milwaukee area's top prep athlete last week? You tell us. You can vote for the Piggly Wiggly Milwaukee Journal Sentinel Athlete of the Week until 3 p.m. Nov. 1. You don't have to be a ...
Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...